QualityStocks would like to highlight Dehaier Medical Systems Limited (NASDAQ: DHRM). Through its subsidiaries, the company engages in the development and distribution of medical devices and related products in the Peoples Republic of China. It offers various medical devices, including mobile medical X-ray image devices, anesthesia machines, and ventilator air compressors, as well as trolleys to hold ventilators and their accessories for mobility; and sterilizers to treat the air from patients.
In the company’s news yesterday,
Dehaier Medical Systems announced that it has obtained State Food and Drug Administration approval for DHR-CPAP-C5, one of the company’s primary proprietary homecare medical devices. The validity period for the SFDA approval is four years.
Continuous positive airway pressure (CPAP) has become the first-line treatment for obstructive sleep apnea syndrome (OSAS), as well as for some forms of central sleep apnea. CPAP works by creating a pneumatic splint for the upper airway. Pressurized air is sent through air tubing and a mask (generally a nose mask) and through the nose to the upper airway by means of a flow generator. This pressurized air keeps the upper airway’s soft tissues from narrowing and collapsing. For proper CPAP treatment, a patient can set high enough flow generator pressures to avoid apneas and hypopneas during all sleep stages and in all sleep positions. The SFDA approval indicates that DHR-CPAP-C5 has met all national health and safety standards, and it will soon be launched in China.
An up-and-coming leader in developing, assembling, marketing, and selling medical devices and homecare medical products in China, Dehaier is focused on offering all-in-one solutions for diagnosing, treating, and assessing OSAS. The company’s DHR-998, used for diagnosis and treatment evaluation, has emerged in the international market after CE Mark approval was received in 2011. The company will continue strengthening its domestic marketing efforts while exploring new business models and strategic partnerships.
One of Dehaier’s critical business strategies involves developing and expanding its market share of homecare medical equipment, based on a belief in the growth potential of the Chinese homecare medical market. Through considerable efforts regarding R&D, product upgrades, product diversification, and patent expansion, the company is positioned to both educate Chinese consumers about the concept of homecare and to serve the burgeoning demand for homecare medical equipment.
The receipt of SFDA approval for DHR-CPAP-C5 is an important step toward providing a complete solution for fighting sleep disorders.
Dehaier is a leading provider of medical products in China, including respiratory and oxygen homecare medical products. The company is engaged in developing and assembling its own branded medical devices and homecare medical products from third-party components. Dehaier additionally distributes products designed and manufactured by other companies, including IMD in Italy, Welch Allyn in the U.S., HEYER in Germany, Temisco in the U.K., eVent Medical in the U.S., and JMS in Japan. The company bases its technology on six patents, nine software copyrights, and proprietary technology.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
